logo

Horizon Pharma Inc (HZNP)



Trade HZNP now with
  Date
  Headline
1/18/2023 8:14:44 AM Horizon : Phase 2 Trial Of Dazodalibep For Treatment Of Sjgren's Syndrome Meets Primary Endpoint
1/4/2023 8:10:53 AM Horizon Says First Patient Enrolled In Phase 2 Trial Of Daxdilimab For Discoid Lupus Erythematosus Treatment
12/20/2022 8:07:46 AM Horizon Therapeutics: Brazilian Health Regulatory Agency Approved UPLIZNA As A Monotherapy For NMOSD
12/8/2022 8:08:24 AM Horizon SaysFirst Subject Dosed In Phase 1 Trial Evaluating HZN-457 For The Treatment Of Gout
11/23/2022 7:57:34 AM Xeris Biopharma Collaborates With Horizon Therapeutics For XeriJect Formulation Of Teprotumumab
11/16/2022 8:20:24 AM Horizon Therapeutics Completes Enrollment Of Phase 3 Trial Of TEPEZZA In Active Thyroid Eye Disease
11/16/2022 8:06:33 AM Horizon Therapeutics Collaborates With Research Institution To Advance Research In Autoimmunity And Inflammation
11/2/2022 7:13:32 AM Horizon Therapeutics Q3 Non-GAAP EPS Declines To $1.25 From $1.74 Prior Year
10/27/2022 8:34:52 AM Q32 Bio, Horizon Therapeutics Announce Dosing Of First Patient In Phase 2 Trial Of ADX-914 For Atopic Dermatitis
10/2/2022 12:35:37 PM Horizon Therapeutics Presents New Data Reveal Molecular Drivers Of TED May Remain Activated In Patients With Low CAS
9/29/2022 8:09:44 AM Horizon Completes Enrollment Of TEPEZZA In Adults With Score Thyroid Eye Disease
9/14/2022 8:09:41 AM Horizon Therapeutics Presents MIRROR Trial Data Of KRYSTEXXA Injection With Methotrexate In Arthritis & Rheumatology